Latest Testing And Inspection Services News

ALS Limited has updated its Dividend Reinvestment Plan price to AUD 22.93 and confirmed the share allocation date as 3 July 2026 for its interim dividend covering the six months to March 2026.

ALS Limited has confirmed its ordinary dividend of AUD 0.231 per share for the six months ending March 2026, introducing multi-currency payment options and appointing Macquarie Securities to manage on-market share purchases for its Dividend Reinvestment Plan.

ALS Limited reported a 25.8% jump in underlying net profit after tax to AUD 381.2 million for FY26, driven by strong commodity testing demand and margin expansion. The company raised its dividend and advanced major hub lab projects while navigating a post-year-end cyber incident.

ALS Limited confirms a fully franked ordinary dividend of 19.4 cents per share and announces the Dividend Reinvestment Plan price at $21.97 with no discount applied.

ALS Limited has announced a partially franked interim dividend of 19.4 cents per share, payable mid-December, alongside a dividend reinvestment plan priced at $21.97 per share with no discount.

ALS Limited has posted a robust first half for FY26 with underlying EBIT growth of 14.7%, driven by strong performance in its Commodities segment and improved Life Sciences results. The company also raised its interim dividend and updated its growth outlook for the year.

ALS Limited has launched a Share Purchase Plan allowing eligible shareholders to invest up to A$30,000 in new shares at a discounted price, following a recent $350 million institutional placement.

ALS Limited has completed a significant institutional placement, issuing over 20.9 million shares at A$16.70 each, bolstering its capital base without the need for full disclosure under the Corporations Act.

ALS Limited has successfully completed a $350 million institutional placement, issuing 21 million new shares to fund key laboratory upgrades and maintain financial flexibility. The company also launched a $40 million share purchase plan to further support its growth ambitions.

ALS Limited has announced an ordinary dividend of AUD 0.197 per share for the half-year ending March 2025, payable in July with flexible currency options for shareholders worldwide.

ALS Limited reported a robust FY25 with $3 billion revenue driven by Life Sciences growth and resilient Commodities, announcing a $350 million equity raise to fund strategic expansion.